About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Ixazomib

Company: Columbia University
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 6 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

6 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 9, 2026

Trial details

Recruiting NCT NCT02343042

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Not yet reported, Not yet reported Karyopharm Therapeutics Inc 300 participants Est. completion 2027-04 25 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT03562169

The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

Not yet reported University of Leeds 406 participants Est. completion 2027-03 91 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT03783416

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Not yet reported Queen Mary University of London 72 participants Est. completion 2027-07-31 1 site Stand-alone

Other conditions: Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
View official trial listing →
Recruiting NCT NCT04068597

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Not yet reported, Not yet reported CellCentric Ltd. 250 participants Est. completion 2027-03-31 39 sites Stand-alone

Other conditions: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
View official trial listing →
Recruiting NCT NCT04305691

Trial of Ixazomib for Kaposi Sarcoma

Not yet reported AIDS Malignancy Consortium 41 participants Est. completion 2029-03-15 11 sites Stand-alone

Other conditions: Kaposi Sarcoma, Skin
View official trial listing →
Recruiting NCT NCT05722405

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 100 participants Est. completion 2028-07-31 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00830869

A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies

Not yet reported Millennium Pharmaceuticals, Inc. 116 participants Est. completion 2012-04-20 7 sites Stand-alone

Other conditions: Advanced Non-hematologic Malignancies
View official trial listing →
Completed NCT NCT00893464

A Study of IXAZOMIB in Adult Patients With Lymphoma

Not yet reported Millennium Pharmaceuticals, Inc. 31 participants Est. completion 2014-10 7 sites Stand-alone

Other conditions: Lymphoma
View official trial listing →
Completed NCT NCT00932698

Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

Not yet reported Millennium Pharmaceuticals, Inc. 60 participants Est. completion 2017-05-23 5 sites Stand-alone

Other conditions: Relapsed and Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT00963820

Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma

Not yet reported Millennium Pharmaceuticals, Inc. 60 participants Est. completion 2014-01 6 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01217957

A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Not yet reported, Not yet reported Millennium Pharmaceuticals, Inc. 65 participants Est. completion 2018-02-02 16 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01318902

Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

Not yet reported Millennium Pharmaceuticals, Inc. 27 participants Est. completion 2018-11-13 10 sites Stand-alone

Other conditions: Light-Chain Amyloidosis
View official trial listing →
Completed NCT NCT01335685

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Not yet reported, Not yet reported Millennium Pharmaceuticals, Inc. 61 participants Est. completion 2016-12-29 20 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01383928

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

Not yet reported, Not yet reported Millennium Pharmaceuticals, Inc. 64 participants Est. completion 2017-11-27 20 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01415882

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

Not yet reported Mayo Clinic 165 participants Est. completion 2025-04-30 3 sites Stand-alone

Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT01454076

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

Not yet reported Millennium Pharmaceuticals, Inc. 112 participants Est. completion 2016-06-16 1 site Stand-alone

Other conditions: Nonhematologic Malignancies, Lymphoma
View official trial listing →
Completed NCT NCT01564537

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Not yet reported Takeda 722 participants Est. completion 2022-02-08 24 sites Stand-alone

Other conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT01645930

Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma

Not yet reported Millennium Pharmaceuticals, Inc. 43 participants Est. completion 2017-04-11 5 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT01659658

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Not yet reported Millennium Pharmaceuticals, Inc. 177 participants Est. completion 2022-07-11 66 sites Stand-alone

Other conditions: Relapsed or Refractory Systemic Light Chain Amyloidosis
View official trial listing →
Withdrawn NCT NCT01660997

MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma

Not yet reported National Cancer Institute (NCI) Est. completion 2014-03-11

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01718743

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Not yet reported M.D. Anderson Cancer Center 64 participants Est. completion 2023-04-12 1 site Stand-alone

Other conditions: Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT01830816

Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Not yet reported Millennium Pharmaceuticals, Inc. 41 participants Est. completion 2016-11-18 11 sites Stand-alone

Other conditions: Multiple Myeloma, Advanced Solid Tumors
View official trial listing →
Completed NCT NCT01850524

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Not yet reported Millennium Pharmaceuticals, Inc. 705 participants Est. completion 2022-06-24 147 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01864018

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Not yet reported, Not yet reported Mayo Clinic 87 participants Est. completion 2023-09-09 2 sites Stand-alone

Other conditions: Amyloidosis, Plasma Cell Myeloma
View official trial listing →
Terminated NCT NCT01887587

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Not yet reported Ehab L Atallah 5 participants Est. completion 2016-02-29 1 site Stand-alone

Other conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
View official trial listing →
Completed NCT NCT01912222

Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction

Not yet reported Millennium Pharmaceuticals, Inc. 48 participants Est. completion 2015-03 4 sites Stand-alone

Other conditions: Advanced Solid Tumors, Hematologic Malignancies
View official trial listing →
Completed NCT NCT01936532

Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)

Not yet reported Nantes University Hospital 42 participants Est. completion 2020-06-04 10 sites

Other conditions: Newly Diagnosed Multiple Myeloma
View official trial listing →
Completed NCT NCT01939899

Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma

Not yet reported Millennium Pharmaceuticals, Inc. 29 participants Est. completion 2017-03-23 14 sites Stand-alone

Other conditions: Follicular Lymphoma
View official trial listing →
Completed NCT NCT01953783

Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB

Not yet reported Millennium Pharmaceuticals, Inc. 7 participants Est. completion 2016-02-09 1 site Stand-alone

Other conditions: Advanced Solid Tumors, Lymphoma
View official trial listing →
Status unknown NCT NCT02004275

Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

Not yet reported, Not yet reported Alliance for Clinical Trials in Oncology 118 participants 336 sites Stand-alone

Other conditions: Multiple Myeloma in Relapse
View official trial listing →
Terminated NCT NCT02030405

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Not yet reported Steven E. Coutre 4 participants Est. completion 2015-11 1 site Stand-alone

Other conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
View official trial listing →
Completed NCT NCT02042989

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

Not yet reported M.D. Anderson Cancer Center 68 participants Est. completion 2020-01-22 1 site

Other conditions: Advanced Cancers
View official trial listing →
Completed NCT NCT02046070

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

Not yet reported Millennium Pharmaceuticals, Inc. 148 participants Est. completion 2018-06-29 24 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02057640

MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma

Not yet reported, Not yet reported Jason Valent 16 participants Est. completion 2018-05-15 2 sites

Other conditions: Multiple Myeloma, Kahler Disease, Plasma-Cell Myeloma, Myelomatosis
View official trial listing →
Completed NCT NCT02070458

Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Not yet reported Case Comprehensive Cancer Center 30 participants Est. completion 2017-08-15 2 sites Stand-alone

Other conditions: Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
View official trial listing →
Completed NCT NCT02119468

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Not yet reported, Not yet reported City of Hope Medical Center 32 participants Est. completion 2022-12-01 5 sites Stand-alone

Other conditions: Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT02158975

Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas

Not yet reported University of Michigan Rogel Cancer Center 13 participants Est. completion 2016-11 1 site

Other conditions: Lymphoma, T-Cell
View official trial listing →
Completed NCT NCT02168101

Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

Not yet reported SCRI Development Innovations, LLC 9 participants Est. completion 2019-02-01 4 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02169791

Nonmyeloablative Haploidentical Transplant Followed by MLN9708

Not yet reported Northside Hospital, Inc. 29 participants Est. completion 2020-07-28 1 site

Other conditions: Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Lymphomas, Multiple Myeloma
View official trial listing →
Terminated NCT NCT02176486

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)

Not yet reported Takeda 12 participants Est. completion 2018-01-19 35 sites Stand-alone

Other conditions: Lupus Nephritis
View official trial listing →
Completed NCT NCT02181413

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Not yet reported Takeda 656 participants Est. completion 2023-09-08 227 sites Stand-alone

Other conditions: Multiple Myeloma, Autologous Stem Cell Transplant
View official trial listing →
Completed NCT NCT02206425

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Not yet reported, Not yet reported Oncotherapeutics 45 participants Est. completion 2018-03-06 12 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02228772

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Not yet reported Massachusetts General Hospital 19 participants Est. completion 2019-11 3 sites

Other conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, T-cell Adult Acute Lymphoblastic Leukemia
View official trial listing →
Completed NCT NCT02250300

MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation

Not yet reported, Not yet reported Mehdi Hamadani 68 participants Est. completion 2020-10-06 1 site

Other conditions: Allogeneic Hematopoietic Stem Cell Transplantation
View official trial listing →
Active, not recruiting NCT NCT02253316

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Not yet reported Washington University School of Medicine 236 participants Est. completion 2026-08-31 10 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT02302846

Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission

Not yet reported M.D. Anderson Cancer Center 5 participants Est. completion 2017-05-30 1 site Stand-alone

Other conditions: Leukemia
View official trial listing →
Completed NCT NCT02312258

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Not yet reported Takeda 706 participants Est. completion 2022-08-26 275 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT02339922

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Not yet reported University of Washington 33 participants Est. completion 2028-01-08 1 site Stand-alone

Obstructive sleep apnea Other conditions: Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
View official trial listing →
Terminated NCT NCT02384746

Phase I Study of the Combination of MLN9708 and Fulvestrant

Not yet reported Dartmouth-Hitchcock Medical Center 9 participants Est. completion 2018-06-10 1 site

Other conditions: Breast Cancer
View official trial listing →
Completed NCT NCT02389517

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Not yet reported University of Chicago 42 participants Est. completion 2024-01 1 site Stand-alone

Other conditions: Plasma Cell Myeloma, Residual Disease
View official trial listing →
Completed NCT NCT02400437

Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia

Not yet reported Dana-Farber Cancer Institute 26 participants Est. completion 2019-11 1 site Stand-alone

Other conditions: Waldenstrom's Macroglobulinemia
View official trial listing →
Completed NCT NCT02406144

Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma

Not yet reported PETHEMA Foundation 316 participants Est. completion 2017-11 74 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02410694

Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Not yet reported Arbeitsgemeinschaft medikamentoese Tumortherapie 90 participants Est. completion 2019-05-02 17 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02412228

Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma

Not yet reported John L. Reagan 12 participants Est. completion 2023-11-09 3 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT02420847

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Not yet reported, Not yet reported M.D. Anderson Cancer Center 57 participants Est. completion 2025-12-31 1 site Stand-alone

Other conditions: Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, Unresectable Transitional Cell Carcinoma
View official trial listing →
Completed NCT NCT02440464

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 57 participants Est. completion 2020-10-01 15 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT02447887

Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)

Not yet reported, Not yet reported Fox Chase Cancer Center 3 participants Est. completion 2017-04-25 1 site Stand-alone

Other conditions: Metastatic Renal Cell Carcinoma, RCC
View official trial listing →
Completed NCT NCT02461888

Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

Not yet reported University of Leeds 112 participants Est. completion 2025-01-19 18 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02477215

Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma

Not yet reported, Not yet reported Parameswaran Hari 38 participants Est. completion 2020-09-17 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT02481310

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Not yet reported, Not yet reported Northwestern University 38 participants Est. completion 2024-07 5 sites Stand-alone

Other conditions: Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation, Plasmablastic Lymphoma
View official trial listing →
Completed NCT NCT02499081

UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment

Not yet reported University of Arkansas 20 participants Est. completion 2018-05-17 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02504359

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Not yet reported OHSU Knight Cancer Institute 11 participants Est. completion 2020-09-09 2 sites Stand-alone

Other conditions: Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT02513498

Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease

Not yet reported Fred Hutchinson Cancer Center 50 participants Est. completion 2018-06-27 6 sites Stand-alone

Other conditions: Chronic Graft Versus Host Disease
View official trial listing →
Terminated NCT NCT02516423

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

Not yet reported Alliance for Clinical Trials in Oncology 11 participants Est. completion 2025-09-30 388 sites Stand-alone

Other conditions: Solitary Osseous Plasmacytoma
View official trial listing →
Status unknown NCT NCT02542657

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

Not yet reported, Not yet reported Joseph Tuscano 30 participants Est. completion 2025-12 3 sites Stand-alone

Other conditions: Myeloma
View official trial listing →
Completed NCT NCT02547662

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Not yet reported Mayo Clinic 17 participants Est. completion 2020-10-30 2 sites Stand-alone

Other conditions: Plasma Cell Leukemia, Plasma Cell Myeloma, Plasmacytoma
View official trial listing →
Withdrawn NCT NCT02578121

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

Not yet reported University of Arkansas Est. completion 2017-01 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Withdrawn NCT NCT02578511

Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)

Not yet reported Ehab L Atallah Est. completion 2018-02-13 1 site Stand-alone

Other conditions: Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma in Complete Remission, Mixed Phenotype Acute Leukemia in Complete Remission
View official trial listing →
Completed NCT NCT02582359

MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age

Not yet reported Massachusetts General Hospital 39 participants Est. completion 2022-04 1 site

Other conditions: Acute Myeloid Leukemia
View official trial listing →
Completed NCT NCT02586038

STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS

Not yet reported Mario Boccadoro 175 participants Est. completion 2023-12 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02619682

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Not yet reported Fred Hutchinson Cancer Center 30 participants Est. completion 2025-10-24 1 site Stand-alone

Other conditions: Plasma Cell Myeloma, Transplant-Related Carcinoma
View official trial listing →
Completed NCT NCT02630030

Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma

Not yet reported Emory University 3 participants Est. completion 2020-09-03 1 site Stand-alone

Other conditions: Glioblastoma
View official trial listing →
Status unknown NCT NCT02632396

Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission

Not yet reported, Not yet reported Emory University 12 participants Est. completion 2024-08 2 sites Stand-alone

Other conditions: Mantle Cell Lymphoma
View official trial listing →
Completed NCT NCT02633059

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Not yet reported, Not yet reported Mayo Clinic 33 participants Est. completion 2022-11-01 8 sites Stand-alone

Other conditions: Loss of Chromosome 17p, Recurrent Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT02697383

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

Not yet reported Memorial Sloan Kettering Cancer Center 14 participants Est. completion 2024-05-08 6 sites Stand-alone

Other conditions: Multiple Myeloma, High Risk Smoldering Multiple Myeloma
View official trial listing →
Completed NCT NCT02765854

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

Not yet reported Emory University 70 participants Est. completion 2023-05-23 4 sites Stand-alone

Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT02831686

A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

Not yet reported Memorial Sloan Kettering Cancer Center 18 participants Est. completion 2020-11-19 7 sites Stand-alone

Other conditions: Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma
View official trial listing →
Terminated NCT NCT02897830

Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma

Not yet reported University Hospital, Toulouse 46 participants Est. completion 2020-08-31 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT02898259

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Not yet reported, Not yet reported Brian Hill 19 participants Est. completion 2022-06-06 2 sites Stand-alone

Other conditions: B Cell Lymphoma, Lymphoma
View official trial listing →
Completed NCT NCT02916771

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Not yet reported Dana-Farber Cancer Institute 61 participants Est. completion 2025-01-08 1 site Stand-alone

Other conditions: Smoldering Multiple Myeloma
View official trial listing →
Completed NCT NCT02917941

A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma

Not yet reported Takeda 34 participants Est. completion 2019-08-31 21 sites Stand-alone

Other conditions: Relapsed and/or Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT02921893

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Not yet reported Mayo Clinic 21 participants Est. completion 2024-05-13 1 site Stand-alone

Other conditions: Plasmacytoma, POEMS Syndrome
View official trial listing →
Completed NCT NCT02924272

Ixazomib Rollover Study

Not yet reported Takeda 32 participants Est. completion 2024-07-03 26 sites Stand-alone

Other conditions: Multiple Myeloma, Lymphoma, Amyloidosis
View official trial listing →
Completed NCT NCT02942095

Study of Ixazomib and Erlotinib in Solid Tumors

Not yet reported M.D. Anderson Cancer Center 9 participants Est. completion 2022-12-07 1 site Stand-alone

Other conditions: Solid Tumors
View official trial listing →
Completed NCT NCT02946047

The Effect of Ixazomib on the Latent HIV Reservoir

Not yet reported, Not yet reported Mayo Clinic 17 participants Est. completion 2019-08-19 1 site Stand-alone

Other conditions: Human Immunodeficiency Virus (HIV)
View official trial listing →
Terminated NCT NCT02993094

Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer

Not yet reported, Not yet reported Arbeitsgemeinschaft medikamentoese Tumortherapie 31 participants Est. completion 2020-08-15 12 sites Stand-alone

Other conditions: Triple-Negative Breast Cancer
View official trial listing →
Completed NCT NCT03012880

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

Not yet reported Mayo Clinic 80 participants Est. completion 2022-12-15 1 site Stand-alone

Other conditions: Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT03082677

Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

Not yet reported Memorial Sloan Kettering Cancer Center 20 participants Est. completion 2021-09-02 1 site Stand-alone

Other conditions: Myeloid Hematologic Malignancy, Lymphoid Hematologic Malignancy
View official trial listing →
Completed NCT NCT03169361

NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"

Takeda 774 participants Est. completion 2022-03-08 1 site

Other conditions: Relapsed/Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT03170882

A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma

Not yet reported Millennium Pharmaceuticals, Inc. 122 participants Est. completion 2021-11-26 111 sites Stand-alone

Other conditions: Relapsed and/or Refractory Multiple Myeloma
View official trial listing →
Terminated NCT NCT03173092

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Not yet reported Takeda 141 participants Est. completion 2026-03-30 21 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT03202628

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Not yet reported Mayo Clinic 8 participants Est. completion 2021-04-13 1 site Stand-alone

Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT03213158

Ixazomib for Desensitization

Not yet reported University of Wisconsin, Madison 10 participants Est. completion 2021-04-16 1 site Stand-alone

Other conditions: Kidney Diseases, End Stage Renal Disease
View official trial listing →
Status unknown NCT NCT03225417

Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

Not yet reported, Not yet reported Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 142 participants Est. completion 2024-12-31 8 sites Stand-alone

Other conditions: Hematopoietic Stem Cell Transplantation, Multiple Myeloma
View official trial listing →
Completed NCT NCT03236792

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

Not yet reported, Not yet reported Icahn School of Medicine at Mount Sinai 28 participants Est. completion 2022-09-20 3 sites Stand-alone

Other conditions: AL Amyloidosis
View official trial listing →
Completed NCT NCT03283917

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Not yet reported M.D. Anderson Cancer Center 21 participants Est. completion 2026-06-17 1 site Stand-alone

Other conditions: Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
View official trial listing →
Completed NCT NCT03323151

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Not yet reported, Not yet reported PrECOG, LLC. 43 participants Est. completion 2023-09-07 14 sites Stand-alone

Other conditions: Mantle-Cell Lymphoma
View official trial listing →
Active, not recruiting NCT NCT03376672

Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

Not yet reported Raija Silvennoinen 120 participants Est. completion 2027-12-31 26 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT03399539

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

Not yet reported Mayo Clinic 8 participants Est. completion 2024-02-23 3 sites Stand-alone

Other conditions: Recurrent Plasma Cell Myeloma, T(11;14)
View official trial listing →
Completed NCT NCT03416374

A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Not yet reported Takeda 45 participants Est. completion 2021-05-28 23 sites Stand-alone

Other conditions: Relapsed and/or Refractory Multiple Myeloma
View official trial listing →
Withdrawn NCT NCT03422874

Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma

Not yet reported Dartmouth-Hitchcock Medical Center Est. completion 2017-08-04 1 site

Other conditions: Neoplasms, Lymphoma
View official trial listing →
Completed NCT NCT03433001

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

Takeda 295 participants Est. completion 2021-06-11 1 site

Other conditions: Relapsed and/or Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT03439293

A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Not yet reported Takeda 61 participants Est. completion 2023-06-26 28 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT03457142

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Not yet reported Roswell Park Cancer Institute 15 participants Est. completion 2024-11-06 3 sites Stand-alone

Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
View official trial listing →
Terminated NCT NCT03492138

Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Not yet reported, Not yet reported Ajai Chari 5 participants Est. completion 2020-01-14 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT03506360

Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Not yet reported Mayo Clinic 13 participants Est. completion 2020-12-10 1 site Stand-alone

Other conditions: Recurrent Plasma Cell Myeloma
View official trial listing →
Terminated NCT NCT03506373

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Not yet reported Mayo Clinic 21 participants Est. completion 2026-02-03 2 sites Stand-alone

Other conditions: Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia
View official trial listing →
Terminated NCT NCT03547700

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Not yet reported, Not yet reported University of Michigan Rogel Cancer Center 11 participants Est. completion 2020-08-27 7 sites Stand-alone

Other conditions: Lymphoma, T-Cell, Peripheral
View official trial listing →
Completed NCT NCT03587662

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Not yet reported M.D. Anderson Cancer Center 30 participants Est. completion 2026-08-04 1 site Stand-alone

Other conditions: Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
View official trial listing →
Terminated NCT NCT03590652

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Not yet reported University of California, San Diego 23 participants Est. completion 2025-07-02 4 sites Stand-alone

Other conditions: Relapsed/Refractory Multiple Myeloma
View official trial listing →
Withdrawn NCT NCT03608501

A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation

Not yet reported Takeda Est. completion 2023-05-31 6 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT03616782

Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)

Not yet reported Ho Sup Lee 98 participants Est. completion 2026-05-31 1 site Stand-alone

Other conditions: Mantle Cell Lymphoma
View official trial listing →
Active, not recruiting NCT NCT03618537

Ixazomib Maintenance Study in Patients With AL Amyloidosis

Not yet reported Memorial Sloan Kettering Cancer Center 17 participants Est. completion 2026-08 8 sites Stand-alone

Other conditions: AL Amyloidosis
View official trial listing →
Completed NCT NCT03619252

Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

Not yet reported Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology 36 participants Est. completion 2021-06-30 1 site Stand-alone

Other conditions: Multiple Myeloma, Pneumococcal Infection, Febrile Neutropenia, Pneumococcal Pneumonia
View official trial listing →
Completed NCT NCT03651128

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Not yet reported Celgene 386 participants Est. completion 2026-04-13 62 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT03669445

Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

Not yet reported University Hospital, Toulouse 45 participants Est. completion 2024-12 12 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT03683277

IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic

Not yet reported Intergroupe Francophone du Myelome 26 participants Est. completion 2023-02-10 28 sites Stand-alone

Other conditions: Multiple Myeloma, Relapsed and Refractory Multiple Myeloma, Genetic Condition
View official trial listing →
Status unknown NCT NCT03720041

Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Not yet reported University of Leeds 740 participants Est. completion 2024-12 110 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT03731832

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Not yet reported GWT-TUD GmbH 66 participants Est. completion 2024-04-22 11 sites Stand-alone

Other conditions: Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT03732703

Myeloma-Developing Regimens Using Genomics (MyDRUG)

Not yet reported, Not yet reported Multiple Myeloma Research Consortium 103 participants Est. completion 2024-12-31 16 sites Stand-alone

Other conditions: Relapsed Refractory Multiple Myeloma
View official trial listing →
Terminated NCT NCT03733691

Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

Not yet reported Oncotherapeutics 19 participants Est. completion 2023-10-19 1 site Stand-alone

Other conditions: Newly Diagnosed Multiple Myeloma
View official trial listing →
Status unknown NCT NCT03746652

Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Not yet reported Hellenic Society of Hematology 50 participants Est. completion 2021-12 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT03748953

Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

Not yet reported Millennium Pharmaceuticals, Inc. 37 participants Est. completion 2023-12-06 10 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT03757221

Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma

Not yet reported University Hospital, Caen 55 participants Est. completion 2024-04-28 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT03763162

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Not yet reported M.D. Anderson Cancer Center 40 participants Est. completion 2027-10-30 1 site Stand-alone

Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT03770260

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

Not yet reported National Cancer Institute (NCI) 8 participants Est. completion 2023-07-06 9 sites Stand-alone

Other conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT03817320

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Not yet reported, Not yet reported Therapeutic Advances in Childhood Leukemia Consortium 24 participants Est. completion 2025-06-30 18 sites Stand-alone

Other conditions: ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
View official trial listing →
Withdrawn NCT NCT03856112

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Not yet reported, Not yet reported National Cancer Institute (NCI) Est. completion 2021-12-31 Stand-alone

Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, t(11;14) Negative
View official trial listing →
Withdrawn NCT NCT03880123

Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

Not yet reported Matthew Ingham Est. completion 2020-11-24 1 site Stand-alone

Obstructive sleep apnea Other conditions: Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma, Ewing Sarcoma, Sarcoma
View official trial listing →
Withdrawn NCT NCT03888534

Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)

Not yet reported Millennium Pharmaceuticals, Inc. Est. completion 2022-08-30 7 sites Stand-alone

Other conditions: Precursor Cell Lymphoblastic Leukemia-lymphoma
View official trial listing →
Active, not recruiting NCT NCT03896737

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Not yet reported European Myeloma Network B.V. 401 participants Est. completion 2027-09-15 24 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT03903406

Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study

Multinational Center for Quality of Life Research, Russia 40 participants Est. completion 2021-11

Other conditions: Relapsed and/or Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT03941860

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Not yet reported National Cancer Institute (NCI) 1 participants Est. completion 2025-01-31 222 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT03942224

Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Not yet reported Emory University 49 participants Est. completion 2026-07-31 1 site Stand-alone

Other conditions: Plasma Cell Myeloma
View official trial listing →
Withdrawn NCT NCT03965624

Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia

Not yet reported Assistance Publique - Hôpitaux de Paris Est. completion 2023-09-01 1 site Stand-alone

Other conditions: Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
View official trial listing →
Status unknown NCT NCT04008888

a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

Not yet reported Institute of Hematology & Blood Diseases Hospital, China 50 participants Est. completion 2020-08-01 1 site Stand-alone

Other conditions: Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Plasmacytoma, Loss of Chromosome 17p, t(14;16), t(4;14), T(14;20), 1Q21 Amplification, Complex Karyotype
View official trial listing →
Active, not recruiting NCT NCT04009109

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Not yet reported Alliance Foundation Trials, LLC. 79 participants Est. completion 2027-06 7 sites Stand-alone

Other conditions: Myeloma, Multiple
View official trial listing →
Completed NCT NCT04028115

Bone Healing During Ninlaro Exposure

Not yet reported Thomas Lund 30 participants Est. completion 2024-04-01 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT04047797

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Not yet reported M.D. Anderson Cancer Center 3 participants Est. completion 2025-04-11 1 site Stand-alone

Other conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
View official trial listing →
Completed NCT NCT04052880

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Not yet reported Larysa Sanchez 20 participants Est. completion 2026-05-27 1 site Stand-alone

Other conditions: Newly Diagnosed Multiple Myeloma
View official trial listing →
Terminated NCT NCT04079738

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

Not yet reported, Not yet reported H Scott Boswell 8 participants Est. completion 2022-02-23 1 site Stand-alone

Other conditions: AML, AML, Adult
View official trial listing →
Active, not recruiting NCT NCT04094961

Ixazomib + Pomalidomide + Dexamethasone In MM

Not yet reported, Not yet reported Omar Nadeem, MD 52 participants Est. completion 2027-01-01 1 site Stand-alone

Other conditions: Multiple Myeloma, Multiple Myeloma in Relapse
View official trial listing →
Terminated NCT NCT04119336

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Not yet reported Andrew Yee, MD 2 participants Est. completion 2022-03-30 2 sites Stand-alone

Other conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
View official trial listing →
Enrolling by invitation NCT NCT04210791

Autologous Stem Cell Transplantation for Patients With AL Amyloidosis

Nanjing University School of Medicine 500 participants Est. completion 2030-12-31 1 site

Other conditions: AL Amyloidosis, Plasma Cell Dyscrasia
View official trial listing →
Completed NCT NCT04217967

Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients

Not yet reported Peking Union Medical College Hospital 211 participants Est. completion 2024-06-30 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT04272775

A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Not yet reported Takeda 14 participants Est. completion 2019-02-15 Stand-alone

Other conditions: Relapsed and/or Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT04328662

A Study of Ninlaro in Real World Clinical Practice in China

Takeda 482 participants Est. completion 2026-02-13 28 sites

Other conditions: Multiple Myeloma, Neoplasms, Plasma Cell
View official trial listing →
Terminated NCT NCT04405167

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Not yet reported University of Pennsylvania 30 participants Est. completion 2025-07-01 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT04463953

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

Not yet reported Institute of Hematology & Blood Diseases Hospital, China 25 participants Est. completion 2022-12-06 1 site Stand-alone

Other conditions: Waldenström Macroglobulinemia
View official trial listing →
Active, not recruiting NCT NCT04790474

Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

Not yet reported Tel-Aviv Sourasky Medical Center 61 participants Est. completion 2028-01-01 7 sites Stand-alone

Other conditions: Multiple Myeloma in Relapse, Refractory Multiple Myeloma
View official trial listing →
Terminated NCT NCT04837131

A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients

Not yet reported Michael M. Pham 4 participants Est. completion 2024-02-23 1 site Stand-alone

Other conditions: Systemic Sclerosis, Scleroderma, Diffuse Systemic Sclerosis, Diffuse Scleroderma, Diffuse Cutaneous Systemic Sclerosis, Diffuse Cutaneous Scleroderma, Progressive Systemic Sclerosis, Progressive Scleroderma, Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma;Progressive, Systemic Sclerosis, Diffuse, Systemic; Sclerosis, Progressive, Scleroderma of Lung, Scleroderma With Pulmonary Involvement, Systemic Sclerosis Pulmonary, Systemic Sclerosis With Lung Involvement, Interstitial Lung Disease, Pulmonary Fibrosis Interstitial
View official trial listing →
Completed NCT NCT04840680

A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)

Takeda 191 participants Est. completion 2023-08-28 20 sites

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT04847453

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Not yet reported National Cancer Institute (NCI) 24 participants Est. completion 2028-06-30 16 sites Stand-alone

Other conditions: Recurrent AL Amyloidosis, Refractory AL Amyloidosis
View official trial listing →
Status unknown NCT NCT04989140

Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide

Not yet reported Peking Union Medical College Hospital 60 participants Est. completion 2024-07-26 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT04998786

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

Not yet reported Nantes University Hospital 75 participants Est. completion 2030-01-01 21 sites Stand-alone

Other conditions: Multiple Myeloma at First Relapse
View official trial listing →
Active, not recruiting NCT NCT05013190

A Study of NINLARO® in Chinese Adults With Multiple Myeloma

Takeda 72 participants Est. completion 2026-12-31 12 sites

Other conditions: Multiple Myeloma
View official trial listing →
Withdrawn NCT NCT05183139

A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma

Not yet reported Takeda Est. completion 2026-12-31 Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT05451771

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Not yet reported, Not yet reported Columbia University 53 participants Est. completion 2027-09 4 sites

Other conditions: AL Amyloidosis
View official trial listing →
Status unknown NCT NCT05477797

Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.

Not yet reported RenJi Hospital 420 participants Est. completion 2026-01-15 1 site Stand-alone

Other conditions: Progression Free Survival, Overall Survival, Maintenance
View official trial listing →
Terminated NCT NCT05675319

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Not yet reported Universitätsklinikum Hamburg-Eppendorf 28 participants Est. completion 2025-03-21 30 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT05882279

A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan

Takeda 330 participants Est. completion 2023-06-09 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Withdrawn NCT NCT06050512

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Not yet reported, Not yet reported Kathleen Dorritie Est. completion 2026-10 Stand-alone

Other conditions: Relapsed and Refractory Multiple Myeloma
View official trial listing →
Not yet recruiting NCT NCT06744894

SIL as Maintenance Therapy in Multiple Myeloma

Not yet reported Navy General Hospital, Beijing 50 participants Est. completion 2030-01-01 Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT05451771

Also known as: Ixazomib, NINLARO

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.